Cargando…
Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study
BACKGROUND & OBJECTIVES: Studies have shown that immunohistochemical (IHC) staining using epidermal growth factor receptor (EGFR) mutation specific antibodies, is an easy and cost-effective, screening method compared with molecular techniques. The purpose of present study was to assess the perce...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892077/ https://www.ncbi.nlm.nih.gov/pubmed/27241644 http://dx.doi.org/10.4103/0971-5916.182621 |
_version_ | 1782435361902821376 |
---|---|
author | Jain, Deepali Iqbal, Sobuhi Walia, Ritika Malik, Prabhat Cyriac, Sunu Mathur, Sandeep R. Sharma, Mehar C. Madan, Karan Mohan, Anant Bhalla, Ashu Pathy, Sushmita Kumar, Lalit Guleria, Randeep |
author_facet | Jain, Deepali Iqbal, Sobuhi Walia, Ritika Malik, Prabhat Cyriac, Sunu Mathur, Sandeep R. Sharma, Mehar C. Madan, Karan Mohan, Anant Bhalla, Ashu Pathy, Sushmita Kumar, Lalit Guleria, Randeep |
author_sort | Jain, Deepali |
collection | PubMed |
description | BACKGROUND & OBJECTIVES: Studies have shown that immunohistochemical (IHC) staining using epidermal growth factor receptor (EGFR) mutation specific antibodies, is an easy and cost-effective, screening method compared with molecular techniques. The purpose of present study was to assess the percentage positivity of IHC using EGFR mutation specific antibodies in lung biopsy samples from patients with primary lung adenocarcinoma (ADC). METHODS: Two hundred and six biopsies of primary lung ADC were subjected to EGFR mutation specific antibodies against del E746-A750 and L858R. Detection of EGFR mutation done by high resolution melting analysis (HRM) was used as gold standard. A concordance was established between molecular and IHC results. Frequency of IHC positivity was assessed. RESULTS: Of the 206 patients, 129 were male and 77 were female patients, with a mean age of 54.1 yr. Fifty five (26.6%) patients (36 men; 19 women) showed positivity for IHC of del E746-A750 (33) and L858R (22). HRM results were available in 14 patients which showed EGFR mutations in correspondence with del E746-750 or L858R in 64.2 per cent cases. Positive cases on HRM were further confirmed by DNA sequencing and fragment analysis. Three patients showed exon20 variation. Two cases were negative for mutation. The genotype of del E746-750 mutation was more common than L858R. A concordance was established between molecular mutation and IHC in 85.7 per cent cases. INTERPRETATION & CONCLUSIONS: In this preliminary study from India mutation specific IHC was used for assessment of mutation status of EGFR. Although the number tested was small, a good concordance was observed between molecular EGFR mutation and IHC expression. IHC methodology is a potentially useful tool to guide clinicians for personalized treatment in lung ADC, especially where facilities for molecular analysis are not readily available and for use in small biopsies where material is scant for molecular tests. |
format | Online Article Text |
id | pubmed-4892077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-48920772016-06-10 Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study Jain, Deepali Iqbal, Sobuhi Walia, Ritika Malik, Prabhat Cyriac, Sunu Mathur, Sandeep R. Sharma, Mehar C. Madan, Karan Mohan, Anant Bhalla, Ashu Pathy, Sushmita Kumar, Lalit Guleria, Randeep Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Studies have shown that immunohistochemical (IHC) staining using epidermal growth factor receptor (EGFR) mutation specific antibodies, is an easy and cost-effective, screening method compared with molecular techniques. The purpose of present study was to assess the percentage positivity of IHC using EGFR mutation specific antibodies in lung biopsy samples from patients with primary lung adenocarcinoma (ADC). METHODS: Two hundred and six biopsies of primary lung ADC were subjected to EGFR mutation specific antibodies against del E746-A750 and L858R. Detection of EGFR mutation done by high resolution melting analysis (HRM) was used as gold standard. A concordance was established between molecular and IHC results. Frequency of IHC positivity was assessed. RESULTS: Of the 206 patients, 129 were male and 77 were female patients, with a mean age of 54.1 yr. Fifty five (26.6%) patients (36 men; 19 women) showed positivity for IHC of del E746-A750 (33) and L858R (22). HRM results were available in 14 patients which showed EGFR mutations in correspondence with del E746-750 or L858R in 64.2 per cent cases. Positive cases on HRM were further confirmed by DNA sequencing and fragment analysis. Three patients showed exon20 variation. Two cases were negative for mutation. The genotype of del E746-750 mutation was more common than L858R. A concordance was established between molecular mutation and IHC in 85.7 per cent cases. INTERPRETATION & CONCLUSIONS: In this preliminary study from India mutation specific IHC was used for assessment of mutation status of EGFR. Although the number tested was small, a good concordance was observed between molecular EGFR mutation and IHC expression. IHC methodology is a potentially useful tool to guide clinicians for personalized treatment in lung ADC, especially where facilities for molecular analysis are not readily available and for use in small biopsies where material is scant for molecular tests. Medknow Publications & Media Pvt Ltd 2016-03 /pmc/articles/PMC4892077/ /pubmed/27241644 http://dx.doi.org/10.4103/0971-5916.182621 Text en Copyright: © Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution NonCommercial ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Jain, Deepali Iqbal, Sobuhi Walia, Ritika Malik, Prabhat Cyriac, Sunu Mathur, Sandeep R. Sharma, Mehar C. Madan, Karan Mohan, Anant Bhalla, Ashu Pathy, Sushmita Kumar, Lalit Guleria, Randeep Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study |
title | Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study |
title_full | Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study |
title_fullStr | Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study |
title_full_unstemmed | Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study |
title_short | Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study |
title_sort | evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: a preliminary study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892077/ https://www.ncbi.nlm.nih.gov/pubmed/27241644 http://dx.doi.org/10.4103/0971-5916.182621 |
work_keys_str_mv | AT jaindeepali evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT iqbalsobuhi evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT waliaritika evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT malikprabhat evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT cyriacsunu evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT mathursandeepr evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT sharmameharc evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT madankaran evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT mohananant evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT bhallaashu evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT pathysushmita evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT kumarlalit evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy AT guleriarandeep evaluationofepidermalgrowthfactorreceptormutationsbasedonmutationspecificimmunohistochemistryinnonsmallcelllungcancerapreliminarystudy |